The targeting of immunosuppressive mechanisms in hematological malignancies.
about
Role of the tumor microenvironment in mature B-cell lymphoid malignanciesImmunotherapy in hematologic malignancies: past, present, and future.l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells.Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remissionT cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.Several immune escape patterns in non-Hodgkin's lymphomas.Microenvironment abnormalities and lymphomagenesis: Immunological aspects.Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3(+)CD8(+) T cells against Various Solid Tumors.Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia.Low-dose salinomycin induces anti-leukemic responses in AML and MLL.The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours.The experiences of protective isolation in patients undergoing bone marrow or haematopoietic stem cell transplantation: systematic review and metasynthesis.High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy.Novel understanding of self-reactive T cells.Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer.PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine.Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab.CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment.The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity.Fungal Pneumonia in Patients with Hematologic Malignancy and Hematopoietic Stem Cell Transplantation.The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma.Frequent adaptive immune responses against arginase-1.Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AMLCD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
P2860
Q26748775-29D505C5-9EA0-489A-90AC-575A430C2BBEQ33593865-84063F19-C9C8-4F6C-9185-DD921E1C61C9Q34979666-6D2BC08D-7D5E-40BD-A49F-4DC5499A119AQ35181654-C5773D3B-FFC2-4B2D-B227-24D187EF392AQ35899277-54E33639-6462-4461-8906-2CCB6BD3DA96Q36060357-E04AA28F-D103-4895-B792-91C5912DD1B7Q36118020-4996EE6E-93F9-46CB-9D6B-4EF7786890F0Q36813010-3EE0AA63-6DE1-4649-B66D-275C033E89FCQ37275289-B66E1D34-EAE2-4BB5-9177-1A24EEB9EBF1Q37587362-61F62C28-538C-46A9-9536-FEF14CD0A5D3Q37641560-15E995ED-B5C5-446C-AEC1-9FEC7F321FC4Q37687407-83EF86BE-A7DC-4124-B936-151A53E2B835Q38543552-BE6BB4CD-A1DB-4627-84F3-F5238B7EF5D2Q38739993-2788794B-FEA2-4818-BF6A-EE00AAF889E0Q38748299-EE74C129-7F64-4070-AAEA-DC612E529B8CQ40436159-6FBE932C-60C1-4632-AD9D-1524CD55C78BQ40966454-EBA548F6-F018-4307-BC2A-E88BFB2FEBCEQ40994145-3DCF582C-60C7-4019-98B6-BAE3A0A56B6CQ41591884-4154813B-5BFE-4F28-936F-FD2D2E05FE89Q41662222-B2F68BC1-5520-4A21-9AF5-FAE21254B425Q42974473-AE834751-95CE-413F-9BB2-C9BF3E74E2BAQ47698782-D258E74C-B6E1-4E56-A73C-073F22C93FBFQ50545414-FDBF6822-88B4-4C29-A432-1DAF9AEB3491Q51742964-4F6AA3DF-7292-4F6C-A910-1E54D8592F9DQ52733766-8E1BFC3F-45AE-4B52-B3E4-3FF1D0C72951Q53396593-A2537E25-7D33-4726-8006-3FB434AA9174Q57039806-0D55EEDE-3072-4F8A-9733-F38D88B348EFQ58610907-CF03EDD7-DDD7-44CE-84BD-22D6872E67C3
P2860
The targeting of immunosuppressive mechanisms in hematological malignancies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The targeting of immunosuppressive mechanisms in hematological malignancies.
@en
type
label
The targeting of immunosuppressive mechanisms in hematological malignancies.
@en
prefLabel
The targeting of immunosuppressive mechanisms in hematological malignancies.
@en
P2860
P356
P1433
P1476
The targeting of immunosuppressive mechanisms in hematological malignancies.
@en
P2093
M H Andersen
P2860
P2888
P304
P356
10.1038/LEU.2014.108
P577
2014-03-18T00:00:00Z
P6179
1020576179